Copyright
©The Author(s) 2022.
World J Clin Oncol. Aug 24, 2022; 13(8): 712-724
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.712
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.712
IM phenotype, n = 52 | EM/UM phenotype, n = 18 | P value | |
Median age in yr | 62.5 (51-86) | 61 (50-84) | 0.574 |
Disease stage | 0.595 | ||
I | 24 | 6 | |
II | 17 | 8 | |
III | 11 | 4 | |
Ethnicity | 0.148 | ||
Chinese | 47 | 13 | |
Malay | 3 | 3 | |
Indian | 1 | 2 | |
Others | 1 | 0 | |
Comorbidities | 0.728 | ||
Yes | 43 | 14 | |
No | 9 | 4 | |
Tumor histology | 0.518 | ||
IDC | 40 | 14 | |
ILC | 7 | 1 | |
Others | 5 | 3 | |
Tumor grade | 0.247 | ||
1 | 16 | 3 | |
2 | 25 | 10 | |
3 | 11 | 5 | |
Median tumor size in mm | 16.5 (1.2 to 70.0) | 20.0 (3.0 to 45.0) | 0.334 |
Lymphovascular invasion | 0.527 | ||
Present | 16 | 7 | |
Absent | 36 | 11 | |
ER intensity | 0.528 | ||
Low | 2 | 0 | |
Moderate | 11 | 2 | |
High | 38 | 15 | |
Negative | 1 | 1 | |
Proportion of tumor cells staining ER-positive | 0.267 | ||
1% to 10% | 4 | 0 | |
11% to 49% | 6 | 1 | |
50% to 89% | 14 | 3 | |
More than 90% | 27 | 14 | |
PR intensity | 0.631 | ||
Low | 5 | 1 | |
Moderate | 9 | 5 | |
High | 31 | 11 | |
Negative | 7 | 1 | |
Proportion of tumor cells staining PR-positive | 0.785 | ||
1% to 10% | 11 | 3 | |
11% to 49% | 8 | 2 | |
50% to 89% | 18 | 7 | |
More than 90% | 11 | 6 | |
HER2 status | 0.495 | ||
Positive | 11 | 2 | |
Negative | 41 | 16 | |
Clinical subtypes | 0.692 | ||
ER+/HER2- | 41 | 14 | |
ER+/HER2+ | 10 | 2 | |
ER-/HER2+ | 1 | 0 |
- Citation: Tan EY, Bharwani L, Chia YH, Soong RCT, Lee SSY, Chen JJC, Chan PMY. Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer. World J Clin Oncol 2022; 13(8): 712-724
- URL: https://www.wjgnet.com/2218-4333/full/v13/i8/712.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i8.712